Recombinant interleukin-6 - Relief Therapeutics Holding

Drug Profile

Recombinant interleukin-6 - Relief Therapeutics Holding

Alternative Names: atexakin alfa; r-IL-6

Latest Information Update: 26 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono; Weizmann Institute of Science
  • Developer FirstString Research; RELIEF THERAPEUTICS Holding
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Interleukin 6 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Peripheral nerve injuries

Most Recent Events

  • 26 Oct 2016 Relief Therapeutics and FirstString Research collaborates for the clinical development of recombinant interleukin-6 (atexakin alfa) in USA
  • 26 Oct 2016 Phase-II clinical trials in Diabetic neuropathies in USA (unspecified route) (Relief Therapeutics pipeline; October 2016)
  • 25 Oct 2016 Relief Therapeutics plans a phase II trial in Diabetic neuropathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top